VERONICA ZAHARIA, M.D.
Osteopathic Medicine in New York, NY
License number
New York 165331
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
237 Veronica Zaharia Md, New York, NY 10003
Phone
(212) 995-0422
(212) 995-0439 (Fax)
(212) 995-0439 (Fax)
Personal information
See more information about VERONICA ZAHARIA at radaris.comName
Address
Phone
14 Drake Rd, Scarsdale, NY 10583
237 20 At 3Rd, New York, NY 10001
237 20 St, New York, NY 10003
2747 Crescent St, Astoria, NY 11102
237 20Th St, New York, NY 10003
Organization information
See more information about VERONICA ZAHARIA at bizstanding.comVeronica Zaharia MD
237 E 20 St APT 1H, New York, NY 10003
Industry:
Health, Wellness and Fitness, Infectious Disease Doctor, Internist
Phone:
(212) 995-0422 (Phone)
Description:
Veronica Zaharia MD is a Health, Wellness and Fitness company located in 237 E 20th St APT 1h, New York, New York, United States.
Veronica Zaharia
Professional information
Dr. Veronica C Zaharia, New York NY - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
Veronica Zaharia MD
237 E 20Th St, New York 10003
(212) 995-0422 (Phone)
237 E 20Th St, New York 10003
(212) 995-0422 (Phone)
Certifications:
Internal Medicine, 2001
Awards:
Healthgrades Honor Roll
Languages:
English, Chinese, French, German, Hungarian, Romanian, Spanish
Education:
Medical School
Universitatea De Medicina Si Farmacie Carol Davila, Facultatea De Medicina
Graduated: 1975
Universitatea De Medicina Si Farmacie Carol Davila, Facultatea De Medicina
Graduated: 1975
Treatment With Erythropoietin Of Bleeding From Benign And Malignant Lesions With Normal And Abnormal Coagulation Parameters
US Patent:
6284260, Sep 4, 2001
Filed:
Jun 17, 1999
Appl. No.:
9/335077
Inventors:
Veronica L. Zaharia Czeizler - New York NY
International Classification:
A61F 202, C07K 14505
US Classification:
424423
Abstract:
A method for the treatment of bleeding from organs involved with benign and malignant lesions by the subcutaneous administration of Erythropoietin. The method makes unnecessary the need for surgery or transfusion of large amounts of blood. The invention provides a conservative treatment for bleeding which works on extensive areas of benign lesions and malignant lesions. The treatment has the following benefits: (1) stops bleeding, (2) eliminates the need for further transfusions, with its attendant complications, (3) allows for treatment as an outpatient, (4) eliminates the need for surgery, (5) allows the patient to return to an excellent quality of life, (6) has no observed side effects, (7) stops bleeding while the patient is fully anti-coagulated, and (8) treats benign and malignant bleeding lesions. Patients with normal or abnormal coagulation/ hemostasis can benefit from the hemostatic benefits of Erythropoietin.
Treatment With Recombinant Human Erythropoietin Of Bleeding In Patients With Normal And Abnormal Hemostasis
US Patent:
6274158, Aug 14, 2001
Filed:
Jun 17, 1999
Appl. No.:
9/335076
Inventors:
Veronica L. Zaharia Czeizler - New York NY
International Classification:
A61F 202, C07K 14505
US Classification:
424423
Abstract:
Recombinant human Erythropoietin is used in a method as a hemostatic agent for the treatment or prevention of bleeding from any organ or body part involved with benign or malignant lesions, surgical traumatic, non-healing/difficult to treat lesions, or radiation injury. The method can control or prevent the bleeding in patients with congenital or acquired disorders of coagulation, platelets, or blood vessels, patients on therapeutic or overdose of anticoagulants or antiplatelet drugs. The method consists of the subcutaneous, intravenous or oral administration of recombinant human Erythropoietin for the purpose of preventing or stopping bleeding.
Method For Improving The Quality Of Life Of Patients By Administration Of Erythropoietin (Rhuepo)
US Patent:
2002016, Nov 14, 2002
Filed:
Apr 26, 2002
Appl. No.:
10/133545
Inventors:
Veronica Zaharia - New York NY, US
International Classification:
A61K038/22
US Classification:
514/012000
Abstract:
A method for providing various benefits with the administration of different quantities of Erythropoietin. The method provides for enhancing the of quality of life by administration of Erythropoietin before a substantial increases in hemoglobin occurs. The improvement in quality of life is independent of the hemopoietic effect. In larger quantities the administration of RhuEPO leads to repair of vascular damage and leads to the redistribution of the iron trapped in storage organs, from where it cannot be used for red blood cell production, into the hemopoietic system leading to enhanced red blood cell production.